Should I Buy AstraZeneca Plc?

Harvey Jones asks whether AstraZeneca plc (LON: AZN) is still bad medicine.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m shopping for shares again, should I pop AstraZeneca (LSE: AZN) (NYSE: AZN.US) into my basket?

The drugs don’t work

If you’re looking for a solid, defensive FTSE 100 stalwart, then look away now, because AstraZeneca isn’t it. The pharmaceutical giant has spent years trying to remedy expiring patents and a failing drugs pipeline, with mixed results. Broker forecasts are dismal, ranging from ‘underperform’, to ‘neutral’, to ‘hold’. Should I buck the trend and buy it?

Last time I looked at AstraZeneca, in October, I wrote that its share price had gone nowhere, slowly, for years. Patents were running out, its pipeline of replacement drugs was blocked, and management had resorted to sacking nearly 10% of its staff to shed weight. Since then, the share price has recovered a modest 9% to £33.07, although the FTSE 100 rose more than 13% over the same period. The longer-term share price story is uglier, with just 1% growth in three years against 22% for the FTSE 100 and an impressive 51% for arch rival GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Profits plunge

AstraZeneca’s Q1 results piled on the misery, with a 13% fall in group revenue to £6.38bn, as it lost exclusivity for key drugs, and a 36% drop in pre-tax profits to $1.3bn. It wasn’t all bad news. Like many FTSE 100 companies, AstraZeneca is having more joy further afield, with sales rising 9% in emerging markets. It boasts 84 products in its drugs pipeline, and recently struck a deal with Amgen, the world’s largest biotechnology company, to develop five biotech drugs. AstraZeneca publishes its Q2 results on Thursday, when the market will be looking to see when its drugs pipeline will wash into the market.

I did like one thing about AstraZeneca: its yield. That was 6.1% in October and remains a peppy 5.6%, covered 2.3 times, easily beating GlaxoSmithKline’s 4.4% yield. There was something else to like, AstraZeneca’s lowly valuation of just 7.8 times earnings, which is almost half Glaxo’s current price-to-earnings ratio of 15 times earnings. So AstraZeneca is either an opportunity, or a great big flashing warning signal. Which is it?

Five better options

Forecast earnings per share (EPS) growth of -19% this calendar year -5% in 2014 suggests the latter. Chief executive Pascal Soriot faces a battle to get this company back into gear, as governments across the West look to contain spiralling drugs budgets. His attempts could stall if AstraZeneca gets sucked into the Chinese bribery scandal, in the wake of GlaxoSmithKlein. The company denies any wrongdoing, but the Chinese authorities are sniffing menacingly. We’ll learn more about AstraZeneca’s prospects on Thursday, but for now, the only compelling reason to buy it is the yield. Mind you, 5.6% is quite compelling.

If you’re looking for a rock solid share to retire on, AstraZeneca isn’t it. You can discover far better stocks in our special report 5 Shares To Retire On. This free report by Motley Fool share analysts names five FTSE 100 favourites to secure your retirement. To find out more, download this report now. It won’t cost you a penny, so click here.

> Harvey owns shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

This forgotten FTSE 100 gem could be the best bargain on the stock market

The FTSE 100 is full to the brim of high-quality businesses. But this Fool has his eye on this 'forgotten'…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Here’s a FTSE 250 stock I’d put 100% of my money into

If this Fool could buy just one stock from the FTSE 250, Games Workshop would be his choice. Here, he…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

2 reasons Warren Buffett might love this stock, and 1 reason he might avoid it like the plague

Warren Buffett's one of the best stock pickers of all time. But would he approve of Barclays shares? This Fool…

Read more »

Union Jack flag triangular bunting hanging in a street
Investing Articles

Down 28% in a week! What’s going on with the share price of this FTSE 250 British icon?

There’s one stock in the FTSE 250 that took a bit of a battering last week. But I’m not surprised,…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

At around £28.50, Shell’s share price looks cheap to me

Shell’s share price still looks undervalued against its fossil-fuel-focused rivals to me, despite it pushing back its carbon reduction targets.

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

433 shares in this FTSE 100 dividend superstar could make me £18,803 in annual passive income!

This overlooked FTSE 100 gem has one of the best yields in the index, looks undervalued, and makes me big…

Read more »

Investing Articles

2 under-the-radar investment trusts I’d buy for a new Stocks and Shares ISA

Here are two fantastic trusts that I'd happily snap up today if I were building a Stocks and Shares ISA…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

If I’d put £1k in Games Workshop shares 5 years ago, here’s how much I’d have now!

Games Workshop shares have proved to be a stellar investment in recent years. Charlie Carman examines whether this trend can…

Read more »